Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit
Home Articles Vol 32,2023 No.4 Detail

Data mining and analysis of adverse drug events signals for Loratadine in children based on FAERS database

Published on Apr. 27, 2023Total Views: 963 times Total Downloads: 304 times Download Mobile

Author: Yi-Bin ZHAI 1 Chuan-Cui LUO 1, 2 Zhen ZENG 1 Ling JIANG 1 Jiang-Ping LI 1 Wen PENG 1 Jian LI 1 Liang YANG 1

Affiliation: 1. Department of Pharmacy, the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China 2. School of Chemistry and Biological Engineering, Yichun University, Yichun 336000, Jiangxi Province, China

Keywords: Loratadine Medications for children Medication error Data mining FAERS database Pharmacovigilance

DOI: 10.19960/j.issn.1005-0698.202304002

Reference: Yi-Bin ZHAI, Chuan-Cui LUO, Zhen ZENG, Ling JIANG, Jiang-Ping LI, Wen PENG, Jian LI, Liang YANG.Data mining and analysis of adverse drug events signals for Loratadine in children based on FAERS database[J].Yaowu Liuxingbingxue Zazhi,2023, 32(4): 367-375.DOI: 10.19960/j.issn.1005-0698.202304002.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective By mining the adverse event (ADE) signals for loratadine in children from real-world data, to find the potential ADE types, and to provide evidence for rational administration of drug.

Methods ADE reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2013 to the second quarter of 2021 were extracted, and the cases under 18 years old who used loratadine were screened out. Proportional reporting ratio (PRR) method and reporting odds ratio (ROR) method were used for data mining, and the Medical Dictionary for Regulatory Activities (MedDRA) was used to systematically classify the ADE signals.

Results A total of 19 237 reports were included after screening, including 1 738 ADE and 186 signals, involving 24 system/organ classifications (injury, poisoning and procedural complications: 22.49%) and 38 standardised MedDRA queries (medication error: 15.74%). Blepharochalasis and agoraphobia with strong signal were not recorded in the drug instructions.

Conclusion It is found after analysis by PRR and ROR methods that although the use of loratadine in children has good safety, there are certain medication errors. It is suggested to strengthen monitoring in clinical medication, use in strict accordance with the provisions of the drug labels, improve the quality of pharmaceutical services, and ensure the safe and effective medication for children.

Full-text
Please download the PDF version to read the full text: download
References

1.Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement[J]. World Allergy Organ J, 2016, 9(1): 33. DOI: 10.1186/s40413-016-0122-3.

2.周鹏翔, 翟所迪, 周薇. 口服组胺H1受体拮抗剂在儿童中合理应用的临床实践指南计划书[J]. 中国循证医学杂志, 2021, 21(1): 90-96. [Zhou PX, Zhai SD, Zhou W. Rational use of oral H1 receptor antagonists in children: a clinical practice guideline protocol[J]. Chinese Journal of Evidence-Based Medicine, 2021, 21(1): 90-96.] DOI: 10.7507/1672-2531.202009169.

3.Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys[J]. Lancet, 2006, 368(9537): 733-743. DOI: 10.1016/S0140-6736(06)69283-0.

4.中华医学会变态反应学分会儿童过敏和哮喘学组, 中华医学会儿科学分会呼吸学组哮喘协作组. 抗组胺H1受体药在儿童常见过敏性疾病中应用的专家共识[J]. 中国实用儿科杂志, 2018, 33(3): 161-170. DOI: 10.19538/j.ek2018030601.

5.Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress[J]. J Allergy Clin Immunol, 2011, 128(6): 1139-1150. DOI: 10.1016/j.jaci.2011.09.005.

6.中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 北京中西医结合学会环境与健康专业委员会皮炎学组, 中国中药协会皮肤病药物研究专业委员会湿疹学组. 抗组胺药治疗皮炎湿疹类皮肤病临床应用专家共识[J]. 中华全科医学, 2021, 19(5): 709-712. https://d.wanfangdata.com.cn/periodical/syqkyx202105002.

7.中华医学会呼吸病学分会哮喘学组. 咳嗽的诊断与治疗指南(2021)[J]. 中华结核和呼吸杂志, 2022, 45(1): 13-46. DOI: 10.3760/cma.j.cn112147-20211101-00759.

8.广东省药学会. 特应性皮炎的合理用药指引[J]. 今日药学, 2022, 32(3): 161-175. DOI: 10.12048/j.issn.1674-229X.2022.03.001.

9.中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童过敏性鼻炎诊疗——临床实践指南[J]. 中国实用儿科杂志, 2019, 34(3): 169-175. DOI: 10.19538/j.ek2019030601.

10.中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识[J]. 中国实用儿科杂志, 2019, 34(9): 721-728. DOI: 10.19538/j.ek2019090601.

11.国家卫生计生委儿童用药专家委员会, 中华医学会儿科学分会呼吸学组, 中国医师协会儿科医师分会儿童呼吸专业委员会, 等. 儿童喘息性疾病合理用药指南[J]. 中华实用儿科临床杂志, 2018, 33(19): 1460-1472. DOI: 10.3760/cma.j.issn.2095-428X.2018.19.005.

12.Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA Adverse Event Reporting System[J]. Int J Med Sci, 2013, 10(7): 796-803. DOI: 10.7150/ijms.6048.

13.Sakaeda T, Kadoyama K, Minami K, et al. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms[J]. Int J Med Sci, 2014, 11(5): 461-465. DOI: 10.7150/ijms.7967.

14.Chen Y, Guo JJ, Steinbuch M, et al. Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods: an empirical study based on the US FDA Adverse Event Reporting System database[J]. Pharm Med, 2008, 22: 359-365. DOI: 10.1007/BF03256733.

15.Van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2002, 11(1): 3-10. DOI: 10.1002/pds.668.

16.Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]. Pharmacoepidemiol Drug Saf, 2001, 10(6): 483-486. DOI: 10.1002/pds.677.

17.Andersson NW, Poulsen HE, Andersen JT. Desloratadine Use During Pregnancy and Risk of Adverse Fetal outcomes:a nationwide cohort study[J]. J Allergy Clin Immunol Pract, 2020, 8(5): 1598-1605. DOI: 10.1016/j.jaip.2020.02.017.

18.Von Laue NC, Schwappach DL, Koeck CM. The epidemiology of preventable adverse drug events: a review of the literature[J]. Wien Klin Wochenschr, 2003, 115(12): 407-415. DOI: 10.1007/BF03040432.

19.National Coordinating Council for Medication Error Reporting and Prevention. About medication er-rors [EB/OL]. [2021-11-10]. https://www.nccmerp.org/about-medication-errors.

20.李瑞霞, 武志昂. 我国儿童用药风险因素的专家调查研究[J].中国药物警戒, 2015, 12(5): 311-313,315. [Li RX, Wu ZA. Expert investigation study on risk factors of medication for children in China[J]. Chinese Journal of Pharmacovigilance, 2015, 12(5): 311-313,315.] DOI: CNKI:SUN:YWJJ.0.2015-05-017.

21.Hoffmann LM, Wegner W, Biasibetti C, et al. Patient safety incidents identified by the caregivers of hospitalized children[J]. Rev Bras Enferm, 2019, 72(3): 707-714. DOI: 10.1590/0034-7167-2018-0484.

22.王雨彤. 中国儿童用药现状、问题与对策[D]. 北京: 北京中医药大学, 2018: 1-104.

23.Billstein-Leber M, Carrillo CJD, Cassano AT, et al. ASHP guidelines on preventing medication errors in hospitals[J]. Am J Health Syst Pharm, 2018, 75(19): 1493-1517. DOI: 10.2146/ajhp170811.

24.Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children[J]. Drug Saf, 2001, 24(2): 119-147. DOI: 10.2165/00002018-200124020-00003.

25.Cataldi M, Maurer M, Taglialatela M, et al. Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticaria[J]. Clin Exp Allergy, 2019, 49(12): 1615-1623. DOI: 10.1111/cea.13500.

26.Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database[J]. Drug Saf, 2002, 25(6): 381-392. DOI: 10.2165/00002018-200225060-00001.

Popular papers
Last 6 months